For these reasons, all concurrent analyses of the utility of 89Zr-DFO-CD4/89Zr-DFO-CD8a PET as predictors of immunotherapeutic response were based on the background corrected tumor-to-heart values. This evidence concerns the gene CD8A and neoplasm.